The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
Tislelizumab is now approved in nine indications in China
Centre of Excellence at Kharel comprises Skill-building Centre and Primary, Secondary and Higher Secondary schools
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
Company hires life science veteran Jessica Cao to join management team
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
Healthcare is timely and personal – and its delivery should be too
A big boost to healthcare efforts of Ayush through NARIP, CCRAS
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
This MoU will further strengthen relations between India and the USA within the framework of international scientific and technological cooperation in fields of mutual interest.
Subscribe To Our Newsletter & Stay Updated
